Combination reperfusion therapy with abciximab and reduced dose reteplase: Results from TIMI 14

European Heart Journal

Volumn 21, Issue 23, 2000, Pages 1944-1953

  Antman, Elliot M ^a   Gibson, C M ^b   De Lemos, J A ^a   Giugliano, R P ^a   McCabe, C H ^a   Coussement, P ^c   Menown, I ^d   Nienaber, C A ^e   Rehders, T C ^e   Frey, M J ^f   Van Der Wieken, R ^g   Andresen, D ^h   Scherer, J ⁱ   Anderson, K ^j   Van De Werf, F ^c   Braunwald, E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d ROYAL VICTORIA HOSPITAL   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f SARASOTA MEMORIAL HOSPITAL   (United States)

^g ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^h VIVANTES KLINIKUM AM URBAN   (Germany)

ⁱ ELI LILLY AND COMPANY   (United States)

^j CENTOCOR INC   (United States)

more..

Author keywords

Acute MI; Antiplatelet therapy; Glycoprotein IIb IIIa inhibition; Thrombolysis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; RETEPLASE;

ACUTE HEART INFARCTION; ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLEEDING TENDENCY; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE REPERFUSION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

EID: 0033695759     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2000.2243     Document Type: Article

References (25)

1. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators
2. Abciximab Improves Both Epicardial Flow and Myocardial Reperfusion in ST Elevation Myocardial Infarction: Observations from the TIMI 14 Trial
3. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction
4. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction
5. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase
6. TIMI frame count: A quantitative method of assessing coronary artery flow
7. Hirudin in acute myocardial infarction: Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial
8. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial
9. ST-segment resolution and infarct related artery patency and flow after thombolytic therapy
10. Extent of early ST segment elevation resolution: A simple but strong predictor of outcome in patients with acute myocardial infarction
11. Extent of early ST segment elevation resolution: A strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens: A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial
12. Relationship of TIMI myocardial perfusion grade to mortality following thrombolytic administration
13. Determinants of coronary blood flowing following thombolytic administration
14. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: Results from TIMI (Thrombolysis in Myocardial Infarction) 14
15. Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reduces gel elastic modulus
16. Augmentation of thrombolysis with antiplatelet drugs
17. GPIIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab
18. A possible benefit of Reopro: Modification of the clot structure
19. Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa
20. In vitro characterization of dethrombosis by abciximab (Reopro)
21. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: Myocardial blush grade. Zwolle Myocardial Infarction Study Group
22. Clinical implications of the 'no reflow' phenomenon: A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction
23. Relation between ST-segment changes and myocardial perfusion evaluated by myocardial contrast echocardiography in patients with acute myocardial infarction treated with direct angioplasty
24. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction